Ferrara Felicetto, Del Vecchio Luigi
Divisione di Ematologia, Ospedale A. Cardarelli, Naples, Italy.
Haematologica. 2002 Mar;87(3):306-19.
Recent investigations in acute myeloid leukemia (AML) have clearly demonstrated that specific karyotypic abnormalities result in distinct biological and clinical entities. We focus on recent advances on biology and treatment of AML with t(8;21).
The information presented here derives from literature data and experience of the authors. The most relevant studies are critically analyzed and discussed.
Peculiar molecular, morphologic, immunophenotypic and epidemiologic findings of AML with t(8;21) as well as current methods for the evaluation of minimal residual disease are presented. Results from current therapeutic options including consolidation chemotherapy or transplantation procedures are critically reviewed.
Innovative therapeutic approaches based on risk-adapted, patient-oriented approaches would be possible in this AML subtype, provided that answers to many unresolved questions are given.
近期对急性髓系白血病（AML）的研究清楚地表明，特定的核型异常会导致不同的生物学和临床实体。我们关注伴有t(8;21)的AML在生物学和治疗方面的最新进展。
此处呈现的信息来源于文献数据及作者的经验。对最相关的研究进行了批判性分析和讨论。
介绍了伴有t(8;21)的AML独特的分子、形态学、免疫表型和流行病学发现，以及当前评估微小残留病的方法。对包括巩固化疗或移植程序在内的当前治疗选择的结果进行了批判性综述。
只要能回答许多未解决的问题，基于风险适应、以患者为导向的方法的创新治疗方法在这种AML亚型中是可行的。
